Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables - Net: 2015-2025

Historic Receivables - Net for Sunshine Biopharma (SBFM) over the last 7 years, with Sep 2025 value amounting to $4.2 million.

  • Sunshine Biopharma's Receivables - Net rose 29.11% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 29.11%. This contributed to the annual value of $3.9 million for FY2024, which is 51.56% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Receivables - Net is $4.2 million, which was up 15.83% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Receivables - Net ranged from a high of $4.2 million in Q3 2025 and a low of $22 during Q3 2022.
  • Over the past 3 years, Sunshine Biopharma's median Receivables - Net value was $3.2 million (recorded in 2024), while the average stood at $3.0 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 98.05% in 2022, then soared by 9,245,895.45% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Receivables - Net (Quarterly) stood at $7,798 in 2021, then spiked by 24,421.07% to $1.9 million in 2022, then surged by 33.48% to $2.6 million in 2023, then skyrocketed by 51.56% to $3.9 million in 2024, then climbed by 29.11% to $4.2 million in 2025.
  • Its Receivables - Net was $4.2 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.4 million in Q1 2025.